Last Updated : January 30, 2020
Today, CADTH has issued final recommendations for:
Lorlatinib (Lorbrena) NSCLC
Funding Request: For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on: crizotinib and at least one other ALK inhibitor, or patients who have progressed on ceritinib or alectinib.
Recommendation: Do not reimburse
Notification to implement target date: February 14, 2020
Atezolizumab (Tecentriq) SCLC
Funding Request: For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity
Recommendation: Do not reimburse
Notification to implement target date: February 14, 2020
Last Updated : January 30, 2020